ASLAN Pharmaceuticals Limited (NASDAQ:ASLN – Free Report)’s stock is scheduled to reverse split on Wednesday, July 3rd. The 1-8 reverse split was announced on Wednesday, July 3rd. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, July 3rd.
ASLAN Pharmaceuticals Stock Performance
NASDAQ:ASLN opened at $0.30 on Monday. ASLAN Pharmaceuticals has a 52 week low of $0.27 and a 52 week high of $3.89. The firm’s fifty day moving average is $0.41 and its 200-day moving average is $0.53. The firm has a market cap of $4.91 million, a P/E ratio of -0.11 and a beta of 1.44.
ASLAN Pharmaceuticals (NASDAQ:ASLN – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.61). As a group, sell-side analysts anticipate that ASLAN Pharmaceuticals will post -2.55 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Report on ASLN
ASLAN Pharmaceuticals Company Profile
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases.
Featured Articles
- Five stocks we like better than ASLAN Pharmaceuticals
- Insider Trades May Not Tell You What You Think
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- What is a Death Cross in Stocks?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- High Dividend REITs: Are They an Ideal Way to Diversify?
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for ASLAN Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.